The effect of metformin on the hypothalamic-pituitary-thyroid axis in women with polycystic ovary syndrome and subclinical hypothyroidism.

Abstract

The effect of metformin treatment on the hypothalamic-pituitary-thyroid axis is relatively weakly understood. This study included 24 prediabetic patients with polycystic ovary syndrome and untreated subclinical hypothyroidism, 12 of whom had already been treated with bromocriptine (5.0-7.5 mg daily). The included patients received metformin (2.55 g daily) for 6 months. Glucose homeostasis markers, serum prolactin, and thyroid function tests were determined before, after 3 months, and at the end of the treatment. Beyond improving glucose homeostasis, metformin administered for 6 months reduced serum levels of thyrotropin but did not affect serum levels of total and free thyroid hormones. Thyrotropin-lowering effect of this agent was stronger in patients not treated with bromocriptine than in patients receiving this drug, and weakly correlated with an improvement in insulin sensitivity. The obtained results indicate that metformin treatment may have an impact on thyrotrope function in hypothyroid patients, probably by enhancing the effect of thyroid hormone action in the pituitary.

• Authors: Robert Krysiak, Bogusław Okopien
• Journal: Journal of clinical pharmacology (J Clin Pharmacol) Vol. 55 Issue 1 Pg. 45-9 (Jan 2015) ISSN: 1552-4604 [Electronic] England
• PMID: 25079765 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2014, The American College of Clinical Pharmacology.

Chemical References

• Thyrotropin
• Metformin

Topics

• Adult
• Female
• Humans
• Hypothalamo-Hypophyseal System
• Hypothyroidism (blood)
• Metformin (pharmacology)
• Middle Aged
• Polycystic Ovary Syndrome (blood)
• Thyroid Gland
• Thyrotropin (blood)